Adjust simvastatin dose according to the SLCO1B1 genotype and lower the risk of adverse effects.

Statins are used in the treatment of hypercholesterolemia, but can cause severe side effects. The SLCO1B1 c.521T>C RealFast™ Assay identifies a genetic variant responsible for simvastatin-induced myopathy.

 

SLCO1B1

 

  • Simvastatin is a widely prescribed statin for lowering LDL cholesterol levels, but may cause dose-dependent adverse events.
  • The c.521T>C variant of the solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene affects the hepatic uptake and metabolism of statins.
  • Patients carrying the c.521C allele have a higher risk of simvastatin-induced myopathy and rhabdomyolysis.
  • Adjustment of simvastatin dose according to the SLCO1B1 c.521T>C genotype is recommended by the Clinical Pharmacogenetic Implementation Consortium (CPIC).

 

ProductREFUnit SizeIFUBrochure
SLCO1B1 c.521T>C RealFast™ Assay7-210
7-213
100 rxn
32 rxn

PDF

PDF